Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The newly developed Human Papillomavirus (HPV) Vaccine, also known as Gardasil 9, has received approval after successfully completed an international Phase 2/3 trial.
Subscribe to our email newsletter
The international phase 2/3 clinical trial, which involved Moffitt Cancer Center faculty, demonstrated that Gardasil 9 vaccination can protect against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease.
According to the trial data, approximately 90% of all cervical cancers worldwide can be prevented if populations are vaccinated with Gardasil 9.
Aimed to compare the safety and effectiveness of Gardasil 9 with Gardasil in more than 14,200 women, of ages 16 to 26, the trial also revealed that Gardasil 9 was 97% effective at preventing high-grade cervical, vulvar and vaginal disease caused by HPV 31, 33, 45, 52 and 58.
Funded by Merck, the research showed that the Gardasil 9 was also effective at preventing disease induced by HPV 6, 11, 16 and 18.
Moffitt Cancer Center, Center for Infection Research in Cancer director Dr Anna R. Giuliano said: "More importantly, the vaccine was found to be safe with no significant vaccine-associated health concerns."